331(top 1%)
PR articles
33.5K(top 0.1%)
PR citations
63(top 1%)
PR h-index
74(top 1%)
h-index
411
documents
46.5K
doc citations
3.6K
citing journals
100
times ranked

Publications

331 peer-reviewed articles • 35,836 peer-reviewed citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance
Cancer, 2025, 131,
4.04Citations (PDF)
2LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC
Future Oncology, 2025, 21, 2007-2016
2.36Citations (PDF)
3Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites
Clinical Cancer Research, 2024, 30, 1945-1958
6.856Citations (PDF)
4Unification of Efforts to Improve Global Access to Cancer Therapeutics: Report From the 2022/2023 Access to Essential Cancer Medicines Stakeholder Summit
JCO Global Oncology, 2024, ,
2.19Citations (PDF)
5A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study
Journal of Thoracic Oncology, 2022, 17, 130-140
2.1129Citations (PDF)
6A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC
JTO Clinical and Research Reports, 2022, 3, 100262
0.912Citations (PDF)
7Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma
JAMA Network Open, 2022, 5, e227240
6.611Citations (PDF)
8Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
New England Journal of Medicine, 2022, 386, 1973-1985
34.52,431Citations (PDF)
92022 Presidential Address: Advancing Equitable Cancer Care Through Innovation
Journal of Clinical Oncology, 2022, 40, 2859-2862
16.91Citations (PDF)
10Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma
British Journal of Cancer, 2022, 127, 1497-1506
5.58Citations (PDF)
11A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck
Clinical Cancer Research, 2022, 28, 5040-5048
6.821Citations (PDF)
12Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives
Oncologist, 2021, 26, 40-48
3.496Citations (PDF)
13Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity
Science Translational Medicine, 2021, 13,
12.572Citations (PDF)
14A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101
Oral Oncology, 2021, 114, 105171
2.417Citations (PDF)
15Evaluation of Oncology Trial Results Reporting Over a 10-Year Period
JAMA Network Open, 2021, 4, e2110438
6.622Citations (PDF)
16Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538
Lung Cancer, 2021, 156, 68-71
2.614Citations (PDF)
17Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors
Clinical Cancer Research, 2021, 27, 5510-5518
6.839Citations (PDF)
18Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC
JTO Clinical and Research Reports, 2021, 2, 100208
0.90Citations (PDF)
19Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma
Clinical Cancer Research, 2021, 27, 5781-5792
6.872Citations (PDF)
20Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer
Lung Cancer, 2021, 159, 56-65
2.620Citations (PDF)
21All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages
Science Immunology, 2021, 6,
13.452Citations (PDF)
22CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
Scientific Reports, 2021, 11,
3.4102Citations (PDF)
23Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience
Oral Oncology, 2021, 122, 105566
2.430Citations (PDF)
24Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901
Clinical Lung Cancer, 2020, 21, 553-561.e1
2.843Citations (PDF)
25Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol
Lancet Oncology, The, 2020, 21, 1589-1601
27.4110Citations (PDF)
26Adjuvant treatment for high‐risk salivary gland malignancies and prognostic stratification based on a 20‐year single institution experience
Health Science Reports, 2020, 3,
1.64Citations (PDF)
27A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study
Cancer, 2020, 126, 3237-3243
4.017Citations (PDF)
28Dose and Volume De-Escalation for Human Papillomavirus–Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional Outcomes
International Journal of Radiation Oncology Biology Physics, 2020, 107, 662-671
1.519Citations (PDF)
29A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
Cancer, 2020, 126, 2146-2152
4.036Citations (PDF)
30Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay
Journal of Thoracic Oncology, 2020, 15, 1306-1316
2.136Citations (PDF)
31Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Clinical Cancer Research, 2019, 25, 5221-5230
6.8152Citations (PDF)
32Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial
Cancer, 2019, 125, 3208-3218
4.095Citations (PDF)
33A pilot study of the pan‐class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer
Head and Neck, 2019, 41, 3842-3849
2.027Citations (PDF)
34Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer
Current Medical Research and Opinion, 2019, 35, 1761-1767
2.11Citations (PDF)
35Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma
OncoImmunology, 2019, 8, e1568813
5.436Citations (PDF)
36A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited‐stage small cell lung cancer in elderly patients versus younger patients
Cancer, 2019, 125, 382-390
4.026Citations (PDF)
37Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Oral Oncology, 2018, 81, 45-51
2.4750Citations (PDF)
38Role of dental hardware in oral cavity squamous cell carcinoma in the low‐risk nonsmoker nondrinker population
Head and Neck, 2018, 40, 784-792
2.030Citations (PDF)
39Feasibility of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Cytology Specimens for Next Generation Sequencing in Non–small-cell Lung Cancer
Clinical Lung Cancer, 2018, 19, 230-238.e2
2.878Citations (PDF)
40Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC
Journal of Thoracic Oncology, 2018, 13, 1171-1182
2.123Citations (PDF)
41Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance)
International Journal of Radiation Oncology Biology Physics, 2018, 101, 177-185
1.546Citations (PDF)
42Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience
Oral Oncology, 2018, 80, 16-22
2.451Citations (PDF)
43The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC
Journal of Thoracic Oncology, 2018, 13, 1183-1188
2.113Citations (PDF)
44Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
Cancer, 2018, 124, 2174-2183
4.057Citations (PDF)
45Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
Oncologist, 2017, 22, 189-198
3.412Citations (PDF)
46Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Clinical Cancer Research, 2017, 23, 4897-4907
6.825Citations (PDF)
47AHNS Series – Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines
Head and Neck, 2017, 39, 201-205
2.014Citations (PDF)
48Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL
Scientific Reports, 2017, 7,
3.419Citations (PDF)
49Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
Lancet Oncology, The, 2017, 18, 1104-1115
27.4411Citations (PDF)
50The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
Journal of Thoracic Oncology, 2017, 12, 194-207
2.1225Citations (PDF)
51Sustained Oligoclonal T Cell Expansion Correlates with Durable Response to Immune Checkpoint Blockade in Lung Cancer
Journal of Cancer Science & Therapy, 2017, 9,
0.26Citations (PDF)
52Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer
International Journal of Radiation Oncology Biology Physics, 2016, 96, 21-29
1.536Citations (PDF)
53Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
New England Journal of Medicine, 2016, 375, 1856-1867
34.54,893Citations (PDF)
54Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE)
Journal of Thoracic Oncology, 2016, 11, 361-369
2.111Citations (PDF)
55Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer
Scientific Reports, 2015, 5,
3.423Citations (PDF)
56Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
New England Journal of Medicine, 2015, 373, 123-135
34.58,108Citations (PDF)
57ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer
Clinical Cancer Research, 2015, 21, 5439-5444
6.8115Citations (PDF)
58HPV-Associated Head and Neck Cancer
Journal of the National Cancer Institute, 2015, 107, djv344
4.6167Citations (PDF)
59Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades
Annals of Oncology, 2015, 26, 198-205
9.914Citations (PDF)
60Lung cancer—a fractal viewpoint
Nature Reviews Clinical Oncology, 2015, 12, 664-675
70.7188Citations (PDF)
61Integrated Genomic Analysis Suggests MLL3 Is a Novel Candidate Susceptibility Gene for Familial Nasopharyngeal Carcinoma
Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1222-1228
1.119Citations (PDF)
62Ex Vivo Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab
Cancer Immunology Research, 2015, 3, 567-574
4.241Citations (PDF)
63Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
New England Journal of Medicine, 2015, 373, 1627-1639
34.59,013Citations (PDF)
64Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups
Lung Cancer, 2015, 90, 281-287
2.66Citations (PDF)
65Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes
Clinical Cancer Research, 2015, 21, 870-881
6.8349Citations (PDF)
66Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma
Oral Oncology, 2015, 51, 53-58
2.432Citations (PDF)
67Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
Clinical Cancer Research, 2015, 21, 632-641
6.8612Citations (PDF)
68Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer
BMC Cancer, 2014, 14,
2.916Citations (PDF)
69CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology, 2014, 9, 214-221
2.151Citations (PDF)
70Race and competing mortality in advanced head and neck cancer
Oral Oncology, 2014, 50, 40-44
2.430Citations (PDF)
71Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer
BMC Cancer, 2014, 14,
2.93Citations (PDF)
72Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer
Oral Oncology, 2014, 50, 825-831
2.48Citations (PDF)
73Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non–Small Cell Lung Cancer
Cancer Research, 2014, 74, 884-895
3.859Citations (PDF)
74DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer
PLoS ONE, 2014, 9, e102112
2.314Citations (PDF)
75Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy
Journal of Geriatric Oncology, 2013, 4, 327-333
1.838Citations (PDF)
76Non–Small-Cell Lung Cancer: Then and Now
Journal of Clinical Oncology, 2013, 31, 981-983
16.928Citations (PDF)
77New Radiotherapy and Chemoradiotherapy Approaches for Non–Small-Cell Lung Cancer
Journal of Clinical Oncology, 2013, 31, 1029-1038
16.977Citations (PDF)
78Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70Gy daily radiotherapy: CALGB 30904
Lung Cancer, 2013, 82, 436-440
2.69Citations (PDF)
79Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma
Oral Oncology, 2013, 49, 277-282
2.411Citations (PDF)
80Phase II Study of Induction Cisplatin and Irinotecan Followed by Concurrent Carboplatin, Etoposide, and Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer, CALGB 30206
Journal of Thoracic Oncology, 2013, 8, 102-108
2.124Citations (PDF)
81A Pooled Analysis of Limited-Stage Small-Cell Lung Cancer Patients Treated with Induction Chemotherapy Followed by Concurrent Platinum-Based Chemotherapy and 70 Gy Daily Radiotherapy: CALGB 30904
Journal of Thoracic Oncology, 2013, 8, 1043-1049
2.151Citations (PDF)
82Oral Chemotherapy in Head and Neck Cancer
Drugs, 2012, 58, 91-97
11.46Citations (PDF)
83Cyclooxygenase-2 (COX-2) As a Predictive Marker for the Use of COX-2 Inhibitors in Advanced Non–Small-Cell Lung Cancer
Journal of Clinical Oncology, 2012, 30, 2019-2020
16.935Citations (PDF)
84A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Clinical Cancer Research, 2012, 18, 2336-2343
6.8114Citations (PDF)
85CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304
Journal of Thoracic Oncology, 2012, 7, 649-654
2.160Citations (PDF)
86Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer
Oncology Reports, 2012, ,
2.820Citations (PDF)
87Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy
Oral Oncology, 2012, 48, 1025-1030
2.413Citations (PDF)
88Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)
Lung Cancer, 2012, 76, 393-396
2.668Citations (PDF)
89Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non–Small-Cell Lung Cancer, A Phase II Trial
Clinical Lung Cancer, 2012, 13, 123-128
2.810Citations (PDF)
90A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531
Lung Cancer, 2011, 74, 258-263
2.62Citations (PDF)
91Pulmonary Toxicity in Stage III Non-Small Cell Lung Cancer Patients Treated With High-Dose (74 Gy) 3-Dimensional Conformal Thoracic Radiotherapy and Concurrent Chemotherapy Following Induction Chemotherapy: A Secondary Analysis of Cancer and Leukemia Group B (CALGB) Trial 30105
International Journal of Radiation Oncology Biology Physics, 2011, 81, e269-e274
1.534Citations (PDF)
92MET and Phosphorylated MET as Potential Biomarkers in Lung Cancer
Journal of Environmental Pathology, Toxicology and Oncology, 2011, 30, 341-354
2.828Citations (PDF)
93Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Organ Preservation of Locoregionally Advanced Oral Cavity Cancer
American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 356-361
1.331Citations (PDF)
94Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B 150304
Journal of Thoracic Oncology, 2011, 6, 1902-1906
2.111Citations (PDF)
95Personalized Treatment of Lung Cancer
Seminars in Oncology, 2011, 38, 274-283
1.939Citations (PDF)
96Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies
Head & Neck Oncology, 2011, 3,
1.843Citations (PDF)
97A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers
Annals of Oncology, 2011, 22, 2304-2309
9.959Citations (PDF)
98Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing Radiation
Molecular Cancer Therapeutics, 2011, 10, 1185-1193
1.982Citations (PDF)
99Crizotinib: ALK/Met inhibitor, oncolytic
Drugs of the Future, 2011, 36, 91
0.114Citations (PDF)
100Chemoradiation for patients with advanced oral cavity cancer
Laryngoscope, 2010, 120, 93-99
1.491Citations (PDF)
101Prognostic Significance of Mucin and p53 Expression in Stage IB Non-small Cell Lung Cancer: A Laboratory Companion Study to CALGB 9633
Journal of Thoracic Oncology, 2010, 5, 810-817
2.124Citations (PDF)
102Factors Associated With Long-term Speech and Swallowing Outcomes After Chemoradiotherapy for Locoregionally Advanced Head and Neck Cancer
JAMA Otolaryngology, 2010, 136, 1226
1.820Citations (PDF)
103Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)
Journal of Thoracic Oncology, 2010, 5, 1644-1648
2.176Citations (PDF)
104A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602)
Journal of Thoracic Oncology, 2010, 5, 380-384
2.150Citations (PDF)
105Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial
Journal of Thoracic Oncology, 2010, 5, 1382-1390
2.1147Citations (PDF)
106Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097)
Journal of Thoracic Oncology, 2010, 5, 1279-1284
2.177Citations (PDF)
107A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia
Gynecologic Oncology, 2010, 117, 37-40
3.096Citations (PDF)
108Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue
Head and Neck, 2010, 32, 1519-1527
2.021Citations (PDF)
109Induction Chemotherapy for Head and Neck Cancer: Recent Data
Oncologist, 2010, 15, 3-7
3.444Citations (PDF)
110Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context
Molecular Cancer Therapeutics, 2010, 9, 2814-2824
1.917Citations (PDF)
111Chemoreirradiation for recurrent salivary gland malignancies
Radiotherapy and Oncology, 2010, 95, 308-311
2.034Citations (PDF)
112Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer
Radiotherapy and Oncology, 2010, 97, 318-321
2.010Citations (PDF)
113Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction
Medical Oncology, 2010, 28, 152-161
2.312Citations (PDF)
114Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
Investigational New Drugs, 2010, 30, 382-386
2.596Citations (PDF)
115The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer
Oncologist, 2009, 14, 1116-1130
3.461Citations (PDF)
116Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck
Oral Oncology, 2009, 45, e155-e160
2.444Citations (PDF)
117Induction Chemotherapy: To Use or Not to Use? That Is the Question
Seminars in Radiation Oncology, 2009, 19, 11-16
2.721Citations (PDF)
118PROCLAIM: A Phase III Study of Pemetrexed, Cisplatin, and Radiation Therapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiation Therapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Locally Advanced Stage III Non–Small-Cell Lung Cancer of Other than Predominantly Squamous Cell Histology
Clinical Lung Cancer, 2009, 10, 193-198
2.850Citations (PDF)
119Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy
Head and Neck, 2009, 31, 1013-1021
2.063Citations (PDF)
120A phase 2 study of cetuximab in combination with docetaxel in chemotherapy‐refractory/resistant patients with advanced nonsmall cell lung cancer
Cancer, 2009, 115, 1713-1722
4.035Citations (PDF)
121MET as a target for treatment of chest tumors
Lung Cancer, 2009, 63, 169-179
2.6117Citations (PDF)
122A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104
Journal of Thoracic Oncology, 2009, 4, 220-226
2.111Citations (PDF)
123Neck Dissection Planning Based on Postchemoradiation Computed Tomography in Patients With Head and Neck Cancer
JAMA Otolaryngology, 2009, 135, 876
1.81Citations (PDF)
124Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer
Journal of Thoracic Oncology, 2009, 4, 1117-1125
2.141Citations (PDF)
125Neck Response to Chemoradiotherapy
JAMA Otolaryngology, 2009, 135, 1133
1.814Citations (PDF)
126Phase II study of sunitinib malate in head and neck squamous cell carcinoma
Investigational New Drugs, 2009, 28, 677-683
2.585Citations (PDF)
127The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium
Investigational New Drugs, 2009, 28, 854-858
2.56Citations (PDF)
128Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
Gynecologic Oncology, 2008, 110, 49-55
3.0154Citations (PDF)
129Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer
Ca-A Cancer Journal for Clinicians, 2008, 58, 32-53
251.5106Citations (PDF)
130Cooperative Group Portfolio in Locally Advanced Non–Small-Cell Lung Cancer: Are We Making Progress?
Clinical Lung Cancer, 2008, 9, 85-91
2.87Citations (PDF)
131Concurrent Chemotherapy and Re-irradiation for Locoregionally Recurrent Head and Neck Cancer
Seminars in Oncology, 2008, 35, 251-261
1.948Citations (PDF)
132Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: Analysis of CALGB phase III trial 9235
Lung Cancer, 2008, 62, 92-98
2.611Citations (PDF)
133Cooperative Group Research Efforts in Lung Cancer: Focus on Early-Stage Non–Small-Cell Lung Cancer
Clinical Lung Cancer, 2008, 9, 9-15
2.87Citations (PDF)
134Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma
Annals of Oncology, 2008, 19, 1650-1654
9.945Citations (PDF)
135Characteristics Associated With Swallowing Changes After Concurrent Chemotherapy and Radiotherapy in Patients With Head and Neck Cancer
JAMA Otolaryngology, 2008, 134, 1060
1.860Citations (PDF)
136Randomized Phase II Study of Carboplatin and Etoposide With or Without thebcl-2Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103
Journal of Clinical Oncology, 2008, 26, 870-876
16.9166Citations (PDF)
137Randomized Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemotherapy and Dose-Escalated Thoracic Conformal Radiotherapy (74 Gy) in Stage III Non–Small-Cell Lung Cancer: CALGB 30105
Journal of Clinical Oncology, 2008, 26, 2457-2463
16.9179Citations (PDF)
138Phase I Study of Bevacizumab Added to Fluorouracil- and Hydroxyurea-Based Concomitant Chemoradiotherapy for Poor-Prognosis Head and Neck Cancer
Journal of Clinical Oncology, 2008, 26, 1732-1741
16.9154Citations (PDF)
139Response to the Methylation Inhibitor Dihydro-5-azacytidine in Mesothelioma Is Not Associated with Methylation of p16INK4a: Results of Cancer and Leukemia Group B 159904
Journal of Thoracic Oncology, 2008, 3, 417-421
2.114Citations (PDF)
140Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430
Journal of Thoracic Oncology, 2008, 3, 1301-1307
2.12Citations (PDF)
141Phase II Randomized Study of Dose-Dense Docetaxel and Cisplatin Every 2 Weeks With Pegfilgrastim and Darbepoetin Alfa With and Without the Chemoprotector BNP7787 in Patients With Advanced Non-small Cell Lung Cancer (CALGB 30303)
Journal of Thoracic Oncology, 2008, 3, 1159-1165
2.115Citations (PDF)
142Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901
Journal of Thoracic Oncology, 2008, 3, 158-162
2.120Citations (PDF)
143Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung Cancer
Journal of Thoracic Oncology, 2008, 3, 59-67
2.17Citations (PDF)
144Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer
Journal of Thoracic Oncology, 2008, 3, 1003-1011
2.166Citations (PDF)
145Arsenic Trioxide in Patients With Adenocarcinoma of the Pancreas Refractory to Gemcitabine
American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 553-556
1.344Citations (PDF)
146Free-Flap Reconstruction in the Doubly Irradiated Patient Population
Plastic and Reconstructive Surgery, 2008, 122, 125-132
1.931Citations (PDF)
147Locally Advanced Non-small Cell Lung Cancer: The Past, Present, and Future
Journal of Thoracic Oncology, 2008, 3, 917-928
2.176Citations (PDF)
148Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B
Journal of Clinical Oncology, 2007, 25, 1698-1704
16.9467Citations (PDF)
149Chemoradiotherapy for Locally Advanced Head and Neck Cancer
Journal of Clinical Oncology, 2007, 25, 4118-4126
16.981Citations (PDF)
150A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma
Cancer Biology and Therapy, 2007, 6, 490-493
4.123Citations (PDF)
151The concurrent chemoradiation paradigm—general principles
Nature Clinical Practice Oncology, 2007, 4, 86-100
6.6400Citations (PDF)
152Aspiration in Chemoradiated Patients With Head and Neck Cancer
JAMA Otolaryngology, 2007, 133, 1289
1.899Citations (PDF)
153Phase II Trial of Paclitaxel–Topotecan–Etoposide Followed by Consolidation Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer: CALGB 30002
Journal of Thoracic Oncology, 2007, 2, 645-651
2.139Citations (PDF)
154Docetaxel and Exisulind in Previously Treated Non-small Cell Lung Cancer (NSCLC) Patients: A Multicenter, Phase II Clinical Trial
Journal of Thoracic Oncology, 2007, 2, 933-938
2.16Citations (PDF)
155The chemoradiation paradigm in head and neck cancer
Nature Clinical Practice Oncology, 2007, 4, 156-171
6.6201Citations (PDF)
156A Phase I Trial of Docetaxel Based Induction and Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer
Cancer Investigation, 2007, 25, 435-444
1.611Citations (PDF)
157Effects of radiotherapy with or without chemotherapy on tongue strength and swallowing in patients with oral cancer
Head and Neck, 2007, 29, 632-637
2.099Citations (PDF)
158Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer
International Journal of Radiation Oncology Biology Physics, 2007, 67, 678-684
1.539Citations (PDF)
159The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium
International Journal of Radiation Oncology Biology Physics, 2007, 69, S1-S3
1.50Citations (PDF)
160A Phase III Study of Surgical Resection and Paclitaxel/Carboplatin Chemotherapy with or Without Adjuvant Radiation Therapy for Resected Stage III Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B 9734
Clinical Lung Cancer, 2007, 8, 268-272
2.846Citations (PDF)
161Key Signaling Pathways and Targets in Lung Cancer Therapy
Clinical Lung Cancer, 2007, 8, S52-S60
2.812Citations (PDF)
162A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores
Quality of Life Research, 2007, 16, 1615-1626
2.129Citations (PDF)
163Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers
International Journal of Oncology, 2006, ,
3.819Citations (PDF)
164Reply to the Letter by Robins et al.
Journal of Thoracic Oncology, 2006, 1, 733
2.10Citations (PDF)
165Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions
International Journal of Oncology, 2006, ,
3.85Citations (PDF)
166Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma
International Journal of Radiation Oncology Biology Physics, 2006, 64, 382-391
1.5241Citations (PDF)
167A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma
Investigational New Drugs, 2006, 24, 141-149
2.516Citations (PDF)
168A phase II trial of O 6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma
Cancer Chemotherapy and Pharmacology, 2006, 58, 634-639
2.136Citations (PDF)
169Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation
Head and Neck, 2006, 28, 64-73
2.0154Citations (PDF)
170S037 Advanced T Stage Is Associated With Improved Swallowing Following Concurrent Chemoradiotherapy in Head and Neck Cancer Patients
JAMA Otolaryngology, 2006, 132, 846
1.80Citations (PDF)
171S115 The Receptor Tyrosine Kinase c-MET Is Mutated in Head and Neck Cancer and Is a Promising Novel Target
JAMA Otolaryngology, 2006, 132, 864
1.80Citations (PDF)
172Similar Outcomes Between African American and Non–African American Patients With Extensive-Stage Small-Cell Lung Carcinoma: Report From the Cancer and Leukemia Group B
Journal of Clinical Oncology, 2006, 24, 407-412
16.943Citations (PDF)
173Reply to the Letter by Robins et al.
Journal of Thoracic Oncology, 2006, 1, 733
2.16Citations (PDF)
174Phase I/II Trial of Gefitinib and Oxaliplatin in Patients With Advanced Colorectal Cancer
American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 340-344
1.334Citations (PDF)
175Phase I Study of Concomitant Chemoradiotherapy with Irinotecan, 5-FU., and Hydroxyurea for Patients with Advanced and/or Recurrent Head and Neck Cancer
Cancer Journal (Sudbury, Mass ), 2005, 11, 140-146
1.810Citations (PDF)
176Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy
International Journal of Radiation Oncology Biology Physics, 2005, 61, 1096-1106
1.547Citations (PDF)
177Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer
Cancer Chemotherapy and Pharmacology, 2005, 56, 421-426
2.118Citations (PDF)
178Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers
Investigational New Drugs, 2005, 23, 489-493
2.565Citations (PDF)
179Current treatments and promising investigations in a multidisciplinary setting
Annals of Oncology, 2005, 16, vi25-vi30
9.910Citations (PDF)
180Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732
Journal of Clinical Oncology, 2005, 23, 3752-3759
16.9181Citations (PDF)
181Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck
Journal of Clinical Oncology, 2005, 23, 5578-5587
16.9394Citations (PDF)
182Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study
Journal of Clinical Oncology, 2005, 23, 585-590
16.9275Citations (PDF)
183Improving outcomes in the treatment of locally-advanced NSCLC with gemcitabine
Lung Cancer, 2005, 50, S10-S12
2.61Citations (PDF)
184A Phase II study of oxaliplatin in urothelial cancer
Urologic Oncology: Seminars and Original Investigations, 2005, 23, 150-154
1.848Citations (PDF)
185Induction Paclitaxel/Carboplatin Followed by Concurrent Chemoradiation Therapy for Unresectable Stage III Non–Small-Cell Lung Cancer: A Limited-Access Study (CALGB 9534)
Clinical Lung Cancer, 2005, 7, 47-53
2.832Citations (PDF)
186Phase II Trial of PS-341 in Patients With Renal Cell Cancer: A University of Chicago Phase II Consortium Study
Journal of Clinical Oncology, 2004, 22, 115-119
16.9145Citations (PDF)
187Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer
Journal of Clinical Oncology, 2004, 22, 1110-1117
16.9174Citations (PDF)
188Analysis of further disease progression in metastatic non-small cell lung cancer: Implications for locoregional treatment
International Journal of Oncology, 2004, ,
3.844Citations (PDF)
189Cetuximab in cancers of the lung and head & neck
Seminars in Oncology, 2004, 31, 61-67
1.925Citations (PDF)
190Concurrent chemoradiotherapy for head and neck cancer
Seminars in Oncology, 2004, 31, 786-793
1.918Citations (PDF)
1919-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium
Investigational New Drugs, 2004, 22, 323-327
2.58Citations (PDF)
192Prioritizing treatment outcomes: Head and neck cancer patients versus nonpatients
Head and Neck, 2004, 26, 163-170
2.080Citations (PDF)
193Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer
Head and Neck, 2004, 26, 447-455
2.0131Citations (PDF)
194Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time
Journal of Magnetic Resonance Imaging, 2004, 20, 122-128
3.4117Citations (PDF)
195Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Journal of Clinical Oncology, 2004, 22, 77-85
16.9776Citations (PDF)
196The Expanding Role of Systemic Therapy in Head and Neck Cancer
Journal of Clinical Oncology, 2004, 22, 1743-1752
16.9203Citations (PDF)
197Induction chemotherapy and radiotherapy in locally advanced non–small cell lung cancer
Hematology/Oncology Clinics of North America, 2004, 18, 81-90
2.26Citations (PDF)
198Swallowing dysfunction—preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: A critical review
International Journal of Radiation Oncology Biology Physics, 2003, 57, 1219-1230
1.5204Citations (PDF)
199A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer
Lung Cancer, 2003, 39, 191-196
2.641Citations (PDF)
200Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Journal of Clinical Oncology, 2003, 21, 1980-1987
16.9573Citations (PDF)
201Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary
Annals of Oncology, 2003, 14, 1306-1311
9.952Citations (PDF)
202Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?
Journal of the National Cancer Institute, 2003, 95, 1370-1375
4.6144Citations (PDF)
203Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5‐Fluorouracil‐ and Hydroxyurea‐Based Regimens: Reversing a Pattern of Failure
Oncologist, 2003, 8, 350-360
3.445Citations (PDF)
204Weekly Carboplatin and Paclitaxel Followed by Concomitant Paclitaxel, Fluorouracil, and Hydroxyurea Chemoradiotherapy: Curative and Organ-Preserving Therapy for Advanced Head and Neck Cancer
Journal of Clinical Oncology, 2003, 21, 320-326
16.9217Citations (PDF)
205An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia
Journal of Clinical Oncology, 2003, 21, 4546-4552
16.9141Citations (PDF)
206A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain
Annals of Oncology, 2003, 14, 656-657
9.938Citations (PDF)
207Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer
Annals of Oncology, 2003, 14, 564-569
9.980Citations (PDF)
208A pilot trial of G3139, a bcl-2 antisense oligonucleotide,and paclitaxel in patients with chemorefractory small-cell lung cancer
Annals of Oncology, 2002, 13, 539-545
9.9151Citations (PDF)
209Phase I Study of Dose-Dense Alternating Doublets in Advanced Non—Small-Cell Lung Cancer
Clinical Lung Cancer, 2002, 3, 265-270
2.82Citations (PDF)
210Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study
Lung Cancer, 2002, 38, 65-71
2.616Citations (PDF)
211An exploration of the pretreatment coping strategies of patients with carcinoma of the head and neck
Cancer, 2002, 95, 98-104
4.074Citations (PDF)
212A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer
Cancer Chemotherapy and Pharmacology, 2002, 50, 1-5
2.113Citations (PDF)
213Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer
Lung Cancer, 2001, 33, S85-S89
2.61Citations (PDF)
214Chemotherapy in the management of squamous-cell carcinoma of the head and neck
Lancet Oncology, The, 2001, 2, 261-269
27.449Citations (PDF)
215Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer
Annals of Oncology, 2001, 12, 343-347
9.928Citations (PDF)
216Concomitant Infusional Paclitaxel and Fluorouracil, Oral Hydroxyurea, and Hyperfractionated Radiation for Locally Advanced Squamous Head and Neck Cancer
Journal of Clinical Oncology, 2001, 19, 1961-1969
16.9148Citations (PDF)
217Locally advanced head and neck cancer
Current Treatment Options in Oncology, 2001, 2, 7-13
3.918Citations (PDF)
218Locally advanced non-small cell lung cancer
Current Treatment Options in Oncology, 2001, 2, 27-42
3.90Citations (PDF)
219Title is missing!
Investigational New Drugs, 2001, 19, 249-254
2.528Citations (PDF)
220Title is missing!
Investigational New Drugs, 2001, 19, 303-310
2.520Citations (PDF)
221Title is missing!
Investigational New Drugs, 2001, 19, 329-333
2.520Citations (PDF)
222Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer
Seminars in Oncology, 2001, 29, 22-27
1.92Citations (PDF)
223Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer
Seminars in Oncology, 2001, 28, 22-27
1.97Citations (PDF)
224Treatment of head and neck and esophageal xenografts employing Alimta and concurrent ionizing radiation
International Journal of Oncology, 2001, ,
3.87Citations (PDF)
225Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non[ndash ]small cell lung cancer
Seminars in Oncology, 2001, 28, 22-27
1.91Citations (PDF)
226Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Non-Small Cell Lung Cancer
Oncologist, 2001, 6, 25-27
3.40Citations (PDF)
227A Phase I Study of STEALTH® Cisplatin (SPI-77) and Vinorelbine in Patients with Advanced Non–Small-Cell Lung Cancer
Clinical Lung Cancer, 2000, 2, 128-132
2.816Citations (PDF)
228Title is missing!
Investigational New Drugs, 2000, 18, 187-191
2.52Citations (PDF)
229Title is missing!
Investigational New Drugs, 2000, 18, 261-263
2.511Citations (PDF)
230A phase I–II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer
Annals of Oncology, 2000, 11, 721-728
9.936Citations (PDF)
231The Role of Cervical Lymphadenectomy After Aggressive Concomitant Chemoradiotherapy
JAMA Otolaryngology, 2000, 126, 950
1.8182Citations (PDF)
232Sex-associated differences in survival of patients undergoing resection for lung cancer
Annals of Thoracic Surgery, 2000, 69, 245-249
2.3131Citations (PDF)
233Lung cancer
Lancet, The, 2000, 355, 479-485
62.1627Citations (PDF)
234Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532
Lung Cancer, 2000, 28, 63-68
2.625Citations (PDF)
235Radiation Therapy With Concomitant Hydroxyurea and Fluorouracil in Stage II and III Head and Neck Cancer
Journal of Clinical Oncology, 1999, 17, 638-638
16.928Citations (PDF)
236Volumetric visualization of head and neck CT data for treatment planning
International Journal of Radiation Oncology Biology Physics, 1999, 44, 693-703
1.525Citations (PDF)
237Title is missing!
Investigational New Drugs, 1999, 17, 97-101
2.533Citations (PDF)
238A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days
Cancer Chemotherapy and Pharmacology, 1999, 43, 385-388
2.117Citations (PDF)
239A Phase II Trial of Oral Trimethylcolchicinic Acid in Patients with Hormone Refractory Prostate Cancer
Prostate Journal, 1999, 1, 195-202
0.01Citations (PDF)
240Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck
1999, 85, 164-170
115Citations (PDF)
241A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors
Cancer, 1999, 86, 528-532
4.04Citations (PDF)
242Quality of Life and Performance in Advanced Head and Neck Cancer Patients on Concomitant Chemoradiotherapy: A Prospective Examination
Journal of Clinical Oncology, 1999, 17, 1020-1020
16.9230Citations (PDF)
243Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer
Investigational New Drugs, 1998, 16, 275-278
2.529Citations (PDF)
244Multimodality therapy in advanced paranasal sinus carcinoma: Superior long-term results
International Journal of Radiation Oncology Biology Physics, 1998, 42, 327
1.55Citations (PDF)
245Clinical Studies in Non-small Cell Lung Cancer: The CALGB Experience
Cancer Investigation, 1998, 16, 72-79
1.614Citations (PDF)
246Enhancing the therapeutic index of concomitant chemoradiotherapy for head and neck cancer
Annals of Oncology, 1998, 9, 471-473
9.98Citations (PDF)
247Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: A long-term analysis
Annals of Oncology, 1998, 9, 647-651
9.914Citations (PDF)
248A Phase II Trial of Vinorelbine in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
American Journal of Clinical Oncology: Cancer Clinical Trials, 1998, 21, 398-400
1.320Citations (PDF)
249Osteoradionecrosis of the jaws as a risk factor in radiotherapy: a report of an eight-year retrospective review.
Oncology Reports, 1998, ,
2.812Citations (PDF)
250Human Papillomavirus Expression and p53 Gene Mutations in Squamous Cell Carcinoma
JAMA Otolaryngology, 1997, 123, 1230-1234
1.849Citations (PDF)
251Thymidylate Synthase Expression and Response to Neoadjuvant Chemotherapy in Patients With Advanced Head and Neck Cancer
Journal of the National Cancer Institute, 1997, 89, 308-313
4.663Citations (PDF)
252Sexual Functioning and Head and Neck Cancer
Journal of Psychosocial Oncology, 1997, 15, 107-122
1.910Citations (PDF)
253Does chemotherapy for head and neck cancer improve symptoms?
Annals of Oncology, 1997, 8, 417-418
9.90Citations (PDF)
254Therapy for locoregionally advanced head and neck cancer
Seminars in Radiation Oncology, 1997, 7, 4-7
2.78Citations (PDF)
255Title is missing!
Quality of Life Research, 1997, 6, 0-0
2.180Citations (PDF)
256Evaluation of neuropathy in patients on suramin treatment
Muscle and Nerve, 1997, 20, 83-91
2.228Citations (PDF)
257Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck
Cancer, 1997, 79, 588-594
4.022Citations (PDF)
258Title is missing!
Investigational New Drugs, 1997, 15, 343-352
2.56Citations (PDF)
259Concomitant 5-FU, hydroxyurea and cisplatin with external beam radiation therapy for locally advanced pancreatic cancer
Oncology Reports, 1997, ,
2.81Citations (PDF)
260Chemoradiotherapy for stage III non-small cell lung cancer
Lung Cancer, 1997, 18, 112
2.60Citations (PDF)
261Combined modality therapy with radiation in NSCLC
Lung Cancer, 1997, 18, 139-140
2.60Citations (PDF)
262Ifosfamide-based three-drug combinations in non-small cell lung cancer
Lung Cancer, 1997, 18, 157
2.60Citations (PDF)
263Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: A potentially curable disease
Annals of Oncology, 1996, 7, 913-918
9.9131Citations (PDF)
264Chemotherapy for squamous cell carcinoma of head and neck: The future is now
Annals of Oncology, 1996, 7, 15-29
9.969Citations (PDF)
265Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus
Cancer Chemotherapy and Pharmacology, 1996, 37, 569-573
2.15Citations (PDF)
266Phase I study of treatment with oral 13- cis -retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin
Cancer Chemotherapy and Pharmacology, 1996, 39, 227-232
2.16Citations (PDF)
267The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale: A study of utility and validity
Cancer, 1996, 77, 2294-2301
4.0582Citations (PDF)
268Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support
1996, 77, 2308-2312
4Citations (PDF)
269Mineralocorticoid insufficiency due to suramin therapy
1996, 78, 2411-2420
25Citations (PDF)
270Etoposide combined with interferon alfa-2b: Novel exploitation of established etoposide pharmacokinetics and pharmacodynamics*
Clinical Pharmacology and Therapeutics, 1996, 59, 349-359
4.72Citations (PDF)
27188 Results of aggressive reirradiation with concomitant chemotherapy in recurrent unresectable head and neck cancer (HNC)
International Journal of Radiation Oncology Biology Physics, 1996, 36, 202
1.50Citations (PDF)
2722117 Organ preservation in stage II and III head and neck cancer utilizing alternate week concomitant chemoradiotherapy
International Journal of Radiation Oncology Biology Physics, 1996, 36, 335
1.50Citations (PDF)
273Anaplastic carcinoma of the thyroid
Annals of Oncology, 1996, 7, 739-744
9.917Citations (PDF)
274How I do it: Head and neck and plastic surgery: Surgical management of the head and neck cancer patient following concomitant multimodality therapy
Laryngoscope, 1995, 105, 97-101
1.430Citations (PDF)
275Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck
Investigational New Drugs, 1995, 13, 249-252
2.53Citations (PDF)
276Interferons and other cytokines in head and neck cancer
Medical Oncology, 1995, 12, 23-33
2.38Citations (PDF)
277Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction
Annals of Surgical Oncology, 1995, 2, 101-106
2.314Citations (PDF)
278A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest
Cancer Chemotherapy and Pharmacology, 1995, 35, 304-312
2.19Citations (PDF)
279Concomitant Chemoradiotherapy, Neutron Boost, and Adjuvant Chemotherapy for Anaplastic Astrocytoma and Glioblastoma Multiforme
Cancer Investigation, 1995, 13, 453-459
1.611Citations (PDF)
280SWALLOWING FUNCTION FOLLOWING MULTISPECIALTY ORGAN PRESERVATION TREATMENT OF ADVANCED HEAD AND NECK-CANCER
Oncology Reports, 1994, ,
2.810Citations (PDF)
281A phase I study of intermittent infusion cladribine in patients with solid tumors
Cancer, 1994, 74, 168-173
4.033Citations (PDF)
282Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer
International Journal of Radiation Oncology Biology Physics, 1994, 29, 153-162
1.528Citations (PDF)
283Chemotherapy, biologies, and chemoprevention as systemic therapies for head and neck cancer
Current Opinion in Oncology, 1994, 6, 277-284
2.13Citations (PDF)
284A PHASE-II TRIAL OF NEOADJUVANT CHEMOTHERAPY AND CONCOMITANT CHEMORADIOTHERAPY FOR THE TREATMENT OF LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER
Oncology Reports, 1994, ,
2.80Citations (PDF)
285Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study
Cancer Chemotherapy and Pharmacology, 1993, 32, 347-352
2.12Citations (PDF)
286Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study
Cancer Chemotherapy and Pharmacology, 1993, 33, 203-209
2.111Citations (PDF)
287Head and Neck Cancer
New England Journal of Medicine, 1993, 328, 184-194
34.51,723Citations (PDF)
288Locoregionally Advanced Paranasal Sinus Carcinoma: Favorable Survival With Multimodality Therapy
JAMA Otolaryngology, 1993, 119, 743-746
1.855Citations (PDF)
2895-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: A clinical and pharmacologic analysis
Annals of Oncology, 1993, 4, 591-595
9.95Citations (PDF)
290Chemotherapy and combined modality therapy in head and neck cancer
Current Opinion in Oncology, 1993, 5, 508-517
2.13Citations (PDF)
291Favorable Long-Term Survival Following Induction Chemotherapy With Cisplatin, Fluorouracil, and Leucovorin and Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Cancer
Journal of the National Cancer Institute, 1992, 84, 877-882
4.699Citations (PDF)
292Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: A feasible and active approach
Annals of Oncology, 1992, 3, 79-81
9.919Citations (PDF)
293Chemotherapy in head and neck cancer
Current Opinion in Oncology, 1992, 4, 504-512
2.18Citations (PDF)
294Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: A randomized phase II study of the cancer and leukemia group B
Annals of Oncology, 1992, 3, 727-732
9.914Citations (PDF)
295Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer
Cancer Chemotherapy and Pharmacology, 1992, 31, 213-216
2.17Citations (PDF)
2965-fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study
Cancer Chemotherapy and Pharmacology, 1992, 29, 178-184
2.122Citations (PDF)
297Mutations of the p53 tumor suppressor gene may predict radiotherapy failure in head and neck cancer patients
International Journal of Radiation Oncology Biology Physics, 1992, 24, 265
1.512Citations (PDF)
298Concomitant Chemoradiotherapy With Cisplatin, 5-Fluorouracil and Hydroxyurea in Poor-Prognosis Head and Neck Cancer
Laryngoscope, 1992, 102, 630-636
1.425Citations (PDF)
299A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients
European Journal of Cancer & Clinical Oncology, 1991, 27, 217-218
0.75Citations (PDF)
300Recent Advances in Radiation Therapy for Head and Neck Cancer
Hematology/Oncology Clinics of North America, 1991, 5, 635-655
2.26Citations (PDF)
301Prognostic factors in advanced head and neck cancer patients undergoing multimodality therapy
Otolaryngology - Head and Neck Surgery, 1991, 105, 62-73
2.379Citations (PDF)
302Chemotherapeutic and biologic radiation enhancement
Current Opinion in Oncology, 1991, 3, 1087-1095
2.17Citations (PDF)
303Survival and Analysis of Failure Following Hydroxyurea, 5-Fluorouracil and Concomitant Radiation Therapy in Poor Prognosis Head and Neck Cancer
American Journal of Clinical Oncology: Cancer Clinical Trials, 1991, 14, 419-426
1.335Citations (PDF)
304Chemotherapy and integrated treatment approaches in head and neck cancer
Current Opinion in Oncology, 1991, 3, 529-534
2.13Citations (PDF)
305A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer
Cancer, 1991, 67, 2253-2257
4.019Citations (PDF)
306Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy
Cancer, 1991, 68, 1101-1105
4.032Citations (PDF)
307Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study
Cancer Chemotherapy and Pharmacology, 1991, 28, 69-73
2.18Citations (PDF)
308Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis
Cancer Chemotherapy and Pharmacology, 1991, 28, 226-227
2.110Citations (PDF)
309Radiotherapy with Concomitant Chemotherapy for Head and Neck Cancer
Hematology/Oncology Clinics of North America, 1991, 5, 753-767
2.218Citations (PDF)
310Review: 5-Fluorouracil cardiotoxicity: A critical review
Annals of Oncology, 1990, 1, 409-414
9.9107Citations (PDF)
311A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia
British Journal of Cancer, 1990, 62, 1015-1017
5.518Citations (PDF)
312Phase ii trial of etoposide and doxorubicin in advanced head and neck cancer
Medical and Pediatric Oncology, 1990, 18, 487-490
0.02Citations (PDF)
313A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer
Cancer, 1990, 66, 206-213
4.034Citations (PDF)
3145-Fluorouracil With Oral Leucovorin and Hydroxyurea and Concomitant Radiotherapy for Stage III Non-Small Cell Lung Cancer
Cancer, 1990, 66, 437-442
4.018Citations (PDF)
315Chemotherapy-related hemolytic-uremic syndrome after the treatment of head and neck cancer. A case report
Cancer, 1990, 66, 1914-1918
4.019Citations (PDF)
316Role of systemic therapy in advanced non-small-cell lung cancer
American Journal of Medicine, 1990, 89, 777-786
2.013Citations (PDF)
317A Randomized Study of Inpatient versus Outpatient Continuous Intravenous Infusion Chemotherapy: Psychosocial Aspects
Selective Cancer Therapeutics, 1989, 5, 137-145
0.414Citations (PDF)
318Heat Shock Proteins in Normal and Leukemic Blood Cells
Journal of Interferon Research, 1989, 9, 195-204
1.55Citations (PDF)
319Radioresistant tumor cell lines derived from head and neck radiation failures
Head and Neck, 1989, 11, 343-348
2.06Citations (PDF)
320Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines
Head and Neck, 1989, 11, 437-442
2.079Citations (PDF)
321A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer
Cancer, 1989, 63, 30-36
4.043Citations (PDF)
322Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing
Cancer, 1989, 63, 1018-1021
4.040Citations (PDF)
323Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer
Cancer, 1989, 63, 1048-1053
4.031Citations (PDF)
324The patterns of failure in patients with pathological stage I and II diffuse histiocytic lymphoma treated with radiation therapy alone
International Journal of Radiation Oncology Biology Physics, 1989, 17, 767-771
1.528Citations (PDF)
325Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: A phase II Illinois Cancer Council study
Investigational New Drugs, 1989, 7,
2.511Citations (PDF)
326Neoadjuvant Vindesine, Etoposide, and Cisplatin for Locally Advanced Non-Small Cell Lung Cancer
Chest, 1989, 96, 110-113
1.056Citations (PDF)
327Implantable Venous Access Device: Use in Patients with Advanced Head and Neck Cancer
Otolaryngology - Head and Neck Surgery, 1988, 99, 578-583
2.39Citations (PDF)
328Concomitant Hydroxyurea, 5‐Fluorouracil, and Radiation Therapy for Recurrent Head and Neck Cancer: Early Results
Otolaryngology - Head and Neck Surgery, 1988, 98, 295-298
2.312Citations (PDF)
329Flow cytometry in hairy cell leukemia before and during interferon alfa-2b therapy
Cancer, 1987, 59, 1987-1991
4.08Citations (PDF)
330Hairy-cell leukemia associated with Hodgkin's disease: A case report
American Journal of Hematology, 1985, 18, 413-419
6.58Citations (PDF)
331Second malignancies in hairy cell leukemia
Cancer, 1985, 56, 1462-1467
4.077Citations (PDF)